Tag: cancer

Posted on November 21, 2018

Single Cell Sequencing: Stat News Meghana Keshavan

Single Cell Sequencing: An Important New Methodology Here’s how single-cell sequencing works: A cancer biopsy is teased apart, and each of the thousands of cells is locked into its own tiny test tube on a microfluidic chip, and then treated with a series of enzymes and chemicals to coax the necessary genetic material out. From […]

Posted on July 27, 2018

Lay Health Workers Helping Cancer Patients Proves Important:

Effect of a Lay Health Worker (LHW) Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With CancerA Randomized Clinical Trial Manali I. Patel, MD, MPH, MS1,2,3,4; Vandana Sundaram, MPH5; Manisha Desai, PhD5; et alVyjeyanthi S. Periyakoil, MD6,7; James S. Kahn, MD2,6; Jay Bhattacharya, MD, PhD4,8; Steven M. Asch, MD, MPH2,6,9; Arnold Milstein, MD, MPH3,6; M. Kate Bundorf, PhD4,8 Author Affiliations JAMA Oncol. Published online July 26, 2018. […]

Posted on May 16, 2018

Micro-RNA Is An Important And Repairable Target For Cancer Prevention: Raymond Rupert MD, MBA.

Micro RNA Is An Important And Repairable Target For Cancer Prevention: Raymond Rupert MD, MBA.  www.rupertcasemanagement.com In epigenetics, micro RNA can turn genes on and off. If a tumour suppressor gene is turned off by micro RNA, then cancer might develop. It is only now that doctors are recognizing how important micro RNA is in […]

Posted on March 26, 2018

Computational Analysis And Intelligent Computing Systems To Assist Oncologists With Personalized Cancer Treatments:

RCM Provides Advanced Computational Analysis to Assist Oncologists in Delivering Personalized Cancer Treatments based on Genetic Markers   The research is clear:  Genetic markers of cancer, which are identified through an analysis of cancer DNA in a lab, can help oncologists personalize treatments for improved outcomes and prolonged survival rates.   Here’s how it works:  Oncologist receive […]

Posted on January 15, 2017

NHS in crisis as cancer operations cancelled due to lack of beds- The Guardian. Jan 15 2017

Patients with cancer are having their operations cancelled by hospitals with increasing regularity as the NHS winter crisis deepens, the Observer can reveal. In an alarming escalation, the previously unthinkable step of calling off cancer surgery has become more commonplace. The revelation will fuel increasingly bitter arguments between the government and NHS staff, both over […]

Posted on January 6, 2017

GETTING MOLECULAR PROFILING TESTING DONE FOR CANCER: Raymond Rupert MD, MBA.

Personalized and targeted treatments for cancer are based on the molecular profiling of the cancer’s DNA. Each patient’s cancer can be unique. Once the driver mutations in the cancer’s DNA are recognized by the lab tests, then specific cancer drugs can be prescribed.  These are known as actionable treatment strategies. These new cancer drugs are […]

Posted on December 4, 2016

REGIONAL CHEMOTHERAPY AS AN OPTION: Raymond Rupert MD,MBA.

REGIONAL CHEMOTHERAPY AS AN OPTION:   Raymond Rupert MD, MBA. Traditional systemic chemotherapy to treat cancer is delivered using a patient’s veins. Systemic chemotherapy is improving, and will continue to improve, with molecular profiling of cancer DNA (which personalizes the delivery of chemotherapy). However, systemic chemotherapy response rates are low and the chemotherapy makes patients […]

Posted on November 16, 2016

CRISPR GENE EDITING USED FOR FIRST TIME TO FIGHT LUNG CANCER: Raymond Rupert MD. MBA.

A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique. On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical trial at […]

Posted on October 28, 2016

EXHAUSTED T CELLS CAN’T DESTROY CANCERS: Raymond Rupert MD, MBA.

What’s the importance of studying T cell exhaustion? These so-called exhausted T cells seem to be one of the main reasons patients can’t get rid of their cancer or clear their infection. T cell exhaustion seems to be a problem not only in natural T cells but also engineered CAR-T cells. Therapeutic CAR-T cells seem to […]

Posted on August 31, 2016

Predicting whether cancer patients will respond to chemo: GENOMIC INSTABILITY is the indicator. STAT News. Raymond Rupert MD, MBA.

BREAST CANCER CELLS UP CLOSE. (NATIONAL CANCER INSTITUTE/MASSEY CANCER CENTER AT VIRGINIA COMMONWEALTH UNIV.) Determining whether a particular cancer patient is likely to respond to radiation or chemotherapy is an exceedingly difficult business, and scientists are working to make the decision more clear. They’ve pinpointed a potential way to predict a cancer patient’s prognosis, and one […]

Posted on June 21, 2016

USING CRISPR TECHNOLOGY TO REPROGRAM IMMUNE T CELLS TO ATTACK CANCER:

  IMMUNOTHERAPY AT THE LEADING EDGE: The new cancer treatment developed at Penn uses gene-editing to modify T cells so they more effectively target certain cancers other than leukemia. Penn appears to have filed a patent on the idea last October, according to European patent records. A proposal for a small safety study will be […]

Posted on April 9, 2016

EXPLORING ALL TREATMENT OPTIONS PAYS OFF: Raymond Rupert MD.MBA. Rupert Case Management Inc.

It is important to consider all treatment options and your insurance coverage when confronting a serious healthcare problem. Case Study: J.F. is a 69 year old male who had a sarcoma surgically removed about 3 years ago. This is a tumour similar to the one that Rob Ford had. Unfortunately, the sarcoma regrew.  Since he […]

Posted on April 1, 2016

ANTIBODY DRUG CONJUGATES TARGET CANCER CELLS: Dr Robert Abraham at Pfizer Pharma.

There are promising new highly targeted therapies called antibody drug conjugates, or ADCs. Currently being investigated by several  companies, including Pfizer, these medicines may be more effective in targeting and destroying tumors when used in combination with current therapies, such as chemotherapy. ADCs represent a continuing shift in the cancer treatment landscape toward personalized medicines […]

Posted on December 1, 2015

NEW BLOOD TEST FOR CANCER IDENTIFIES THE PRESENCE AND ORIGIN OF THE TUMOUR:

Dr. D. James Morré, PhD – Co-Founder and Director of Research: Discovery of the ENOX2 Serum Cancer Marker The ENOX proteins comprise a family of cell surface enzymes that are essential to the growth phase of cell proliferation. One member of this family, ENOX2, is universally produced by cancer cells after malignant transformation due to […]

Posted on October 6, 2015

Economic value of the utility-expansion for new cancer drugs approved in Canada from 2004 to 2014.

Summary Authors: Kimberley Tran (M.A.); Brett J Skinner (Ph.D.) In the Canadian health technology assessment (HTA) process, drugs are evaluated for clinical and cost-effectiveness following Health Canada marketing approval. Usually, each drug indication is evaluated by HTA bodies individually in line with the specific indication granted by Health Canada. However, when a cancer drug is […]

Posted on May 19, 2015

FUNDING FOR CANCER MEDICATIONS TAKEN AT HOME:

 A Business Case for the Universal coverage of Oral Cancer Medicines in Ontario and Atlantic Canada, The Cameron Institute D. Wayne Taylor, Ph.D., F.CIM Executive Director There are more cancer survivors in the country than ever before; 62% of new cancer patients are expected to survive for 5 years or more. Many are living much […]

Posted on May 12, 2015

Tumour Vaccines: The Future Is Here- Raymond Rupert MD. MBA.

Something for patients and oncologists to consider in their future treatment plans. Vaxil Biotherapeutics has developed and is testing a cancer vaccine. Immucin is the vaccine. The vaccine is very innovative. It attacks the MUC1 marker on the tumour cell. About 90% of tumours have MUC1 markers. By attacking this marker, it makes the tumour […]

Posted on January 12, 2015

PATIENT’S RIGHTS TO EXPERIMENTAL DRUGS Raymond Rupert MD, MBA, Rupert Case Management Inc.

Critically ill patients and their doctors who have tried everything eventually run out of options. In order to increase their options some US states have passed new “Right To Try” laws. Patients such as Larry Kutt, age 65, of Lyon Colorado who has advanced blood cancer (multiple myeloma) has run out of options. Now under […]

Posted on December 25, 2012

BIG TIME CHANGES FOR CLINICAL TRIALS:

The treatment of cancer is changing dramatically. The new drugs target a cancer gene fundamental to tumour growth. This is known as the molecular target. Many authorities see this as the start of the genetic age in cancer research and personalized cancer treatment. One big change is that clinical trials of new cancer drugs will […]